Nintedanib use may be associated with acute aortic syndrome, suggesting that diagnostic work-up for AAS should be considered in patients developing acute chest or back pain while on this medication.
May prompt AAS evaluation in nintedanib users with acute pain; leaves open causal association pending controlled studies.
We report a 74-year-old patient who developed an acute aortic syndrome (AAS) with intramural haematoma (IMH) during treatment with nintedanib, a tyrosine kinase inhibitor. As we suspected a role for nintedanib, this was immediately interrupted. Four months later, a computed tomographic angiography (CTA) showed significant regression of the IMH. Therefore, we state that, when patients use nintedanib and develop acute chest or back pain, diagnostic work-up for AAS should be considered. Furthermore, other risk factors for AAS, such as hypertension, genetic diseases and comedication should be taken into account when prescription of medication of this class is considered.
No takes yet. Share an insight, caveat, or question.
Willems et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: